Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RPS6KA2 | Q15349 | 5/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.39 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.39 |
| ▸ | RPS6KA6 | Q9UK32 | 2/20 | 0.39 |
| ▸ | SCD | O00767 | 3/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.38 |
| ▸ | BUB1 | O43683 | 4/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060778 | 1.00 | ALDH1A1 (0.41) | ALDH1A1RPS6KA2RPS6KA3RPS6KA1RPS6KA6 | |
| SCHEMBL950040 | 0.94 | KLKB1 (0.36) | ALDH1A1RPS6KA2RPS6KA3RPS6KA1RPS6KA6 | |
| SCHEMBL950481 | 0.93 | ALDH1A1 (0.42) | ALDH1A1RPS6KA2RPS6KA3RPS6KA1RPS6KA6 | |
| SCHEMBL949097 | 0.91 | RPS6KA2 (0.40) | ALDH1A1RPS6KA2RPS6KA3RPS6KA1RPS6KA6 | |
| SCHEMBL15520154 | 0.90 | KDR (0.35) | ALDH1A1SCDSCD5KDR | |
| SCHEMBL960971 | 0.89 | KLKB1 (0.32) | ALDH1A1KLKB1KDR | |
| SCHEMBL949993 | 0.89 | KDR (0.43) | ALDH1A1RPS6KA2RPS6KA3RPS6KA1RPS6KA6 | |
| SCHEMBL951282 | 0.89 | ALDH1A1 (0.40) | ALDH1A1RPS6KA2RPS6KA3RPS6KA1RPS6KA6 | |
| SCHEMBL986116 | 0.89 | ALDH1A1 (0.45) | ALDH1A1RPS6KA2RPS6KA3RPS6KA1RPS6KA6 | |
| SCHEMBL948537 | 0.88 | KDR (0.40) | ALDH1A1RPS6KA2RPS6KA3RPS6KA1RPS6KA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260009798-A1 | METHODS AND SYSTEMS FOR TREATING DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR | ACRIVON THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| US-20250262214-A1 | INTERMITTENT DOSING REGIMEN FOR AZENOSERTIB IN TREATING CANCER | ZENO MANAGEMENT, INC. | 2025-08-21 | — | — | US | claimed |
| WO-2025151786-A1 | METHODS AND SYSTEMS FOR TREATING DISEASE USING AN ATR/CHEK1 SIGNALING PATHWAY INHIBITOR | ACRIVON THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4555325-A2 | METHODS AND SYSTEMS FOR TREATING DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR | Acrivon Therapeutics, Inc. (US) | 2025-05-21 | — | — | EP | claimed |
| CN-119768688-A | Methods and systems for treating diseases using inhibitors of ATR/CHK1 signaling pathway | 亚克力冯治疗公司 | 2025-04-04 | — | — | CN | claimed |
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | claimed |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2025-03-11 | — | — | US | claimed |
| CN-119233822-A | Methods of treating cancer using alkylating agent prodrugs and cell cycle inhibitors in combination | 深圳艾欣达伟医药科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| WO-2023076485-A1 | COMBINATION THERAPIES COMPRISING WEE1 INHIBITORS AND DNA DAMAGE RESPONSE (DDR) INHIBITORS | RECURIUM IP HOLDINGS, LLC (US) | 2023-05-04 | — | — | WO | claimed |
| EP-4121564-A1 | BIOMARKERS FOR SACITUZUMAB GOVITECAN THERAPY | Immunomedics, Inc. (US) | 2023-01-25 | — | — | EP | claimed |
| WO-2022258975-A1 | CANCER METHODS | UNIVERSITY COLLEGE LONDON (GB) | 2022-12-15 | — | — | WO | claimed |
| CN-115398010-A | Biomarkers for Goxatuzumab therapy | 免疫医疗公司 | 2022-11-25 | — | — | CN | claimed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| US-20220211783-A1 | GMCI AND DDRI COMBINATION THERAPY FOR TREATING CANCER | TRINITY CAPITAL INC., AS AGENT | 2022-07-07 | — | — | US | claimed |
| EP-3955943-A1 | GMCI AND DDRI COMBINATION THERAPY FOR TREATING CANCER | Candel Therapeutics, Inc. (US) | 2022-02-23 | — | — | EP | claimed |
| EP-2294065-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | Vernalis (R&D) Ltd. (GB) | 2011-03-16 | — | — | EP | claimed |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2011-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | ALDH1A1 1260/4885RPS6KA2 1164/4885RPS6KA3 1354/4885 |
| US-20260009798-A1 | METHODS AND SYSTEMS FOR TREATING DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR | CHEK1, CHEK2, CKS1B | ALDH1A1 4850/4885RPS6KA2 218/4885RPS6KA3 352/4885 |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | CHEK1, CHEK2, BUB1 | ALDH1A1 1503/4885RPS6KA2 666/4885RPS6KA3 523/4885 |
| US-20250262214-A1 | INTERMITTENT DOSING REGIMEN FOR AZENOSERTIB IN TREATING CANCER | ABL1, KRAS, JAK2 | ALDH1A1 1948/4885RPS6KA2 1435/4885RPS6KA3 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.